Novo Nordisk Initiates Share Repurchase Program
Ticker: NONOF · Form: 6-K · Filed: Dec 9, 2024 · CIK: 353278
Sentiment: neutral
Topics: share-repurchase, regulation, corporate-action
TL;DR
Novo Nordisk is buying back its own stock under a new program.
AI Summary
On December 9, 2024, Novo Nordisk A/S announced the initiation of a share repurchase program. This program is being conducted in accordance with European regulations, specifically Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052. The program was initiated on November 11, 2024.
Why It Matters
Share repurchases can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a share repurchase program, which is a common corporate action.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant and issuer of the announcement
- Regulation No 596/2014 (regulation) — Governing regulation for the share repurchase program
- Commission Delegated Regulation (EU) 2016/1052 (regulation) — Specific regulation for the share repurchase program
FAQ
When was the share repurchase program initiated?
The share repurchase program was initiated on November 11, 2024.
What is the purpose of this filing?
This filing is a Report of Foreign Private Issuer (Form 6-K) to announce the initiation of a share repurchase program.
Under which regulations is the share repurchase program being conducted?
The program is being conducted in accordance with Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052.
What is the company's principal executive office address?
The principal executive offices are located at Novo Allé 1 DK- 2880, Bagsvaerd Denmark.
Is Novo Nordisk filing an annual report under Form 20-F or 40-F?
Novo Nordisk indicates it files annual reports under Form 20-F.
Filing Stats: 643 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-12-09 12:02:26
Filing Documents
- f6k_120924.htm (6-K) — 28KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006813.txt ( ) — 167KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: December 9, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer